Judy Boughey

Sep 14, 2024 | nature.com | Katia Khoury |Hope Rugo |Rita Nanda |Alexandra Zimmer |Judy Boughey |Christos Vaklavas | +11 more

AbstractAmong the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer to further these goals, testing promising new agents while optimizing individual outcomes. Here we tested datopotamab–deruxtecan (Dato-DXd) in the I-SPY2.2 trial for patients with high-risk stage 2/3 breast cancer.

Sep 13, 2024 | nature.com | Rita Nanda |Hope Rugo |Judy Boughey |Kevin Kalinsky |Christos Vaklavas |Claudine Isaacs | +8 more

AbstractSequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity.

Sep 22, 2023 | onclive.com | Judy Boughey

Judy C. Boughey, MD, breast surgical oncologist, division chair, Breast and Melanoma Surgical Oncology, chair, Breast Cancer Disease Group, Mayo Clinic Comprehensive Cancer Center, discusses key characteristics that define the ideal population for surgical de-escalation among patients with breast cancer. Within the breast cancer field, there is a growing emphasis on tailoring surgical interventions to individual patients to minimize potential surgical complications, Boughey begins.

Apr 18, 2023 | nature.com | Xue Wang |David Hillman |Heikki Joensuu |Judy Boughey |Minetta C. Liu |James Ingle | +1 more

This study was conducted in accordance with recognized ethical guidelines, including the U.S. Common Rule. The FinXX study was approved by an Institutional Review Board at the Helsinki University Hospital (approvals 264/13/03/02/2014 and HUS/903/2017). The patients who participated in the FinXX trial (NCT00114816) signed a written informed consent to the trial participation and consent to allow the use of their tumor tissue for FinXX trial-related research purposes.

Feb 3, 2023 | onclive.com | Judy Boughey

Judy C. Boughey, MD, breast surgical oncologist, division chair, Breast and Melanoma Surgical Oncology, chair, Breast Cancer Disease Group, Mayo Clinic Comprehensive Cancer Center, discusses the significance of results from the phase 2 ACOSOG Z11102 (Alliance) trial (NCT01556243) evaluating breast conserving therapy (BCT) in multiple ipsilateral breast cancer (MIBC).